E-viri
Recenzirano
-
Berk, Veli; Ismailogullari, Sevda; Donmez, Halil; Karaca, Halit; Inanc, Mevlude; Ozkan, Metin
Medical oncology (Northwood, London, England), 06/2012, Letnik: 29, Številka: 2Journal Article
Bevacizumab, which is a humanized monoclonal antibody against vascular endothelial growth factor, is used to treat metastatic cancers of the colon. Adverse effects common with bevacizumab treatment are hypertension, arterial-venous thrombosis, bleeding, gastrointestinal perforation, and proteinuria. To date, there have been no reports of refractory seizure following treatment with bevacizumab. We describe a patient who presented with refractory generalized tonic-clonic seizures after receiving last dose of bevacizumab for treatment of metastatic colorectal cancer with FOLFIRI and bevacizumab regimen.
